IPO Details

About Company

Pramodini Medicare Ltd. is a healthcare company incorporated in 2010, focusing on the production and distribution of pharmaceutical products, including generic medications and over-the-counter drugs. The company operates under the larger umbrella of the Pramodini Group, which has a diverse portfolio in various sectors. Pramodini Medicare boasts a comprehensive product portfolio that includes a wide range of therapeutic areas, catering to both domestic and international markets. The company's manufacturing facilities are equipped with advanced technology, ensuring compliance with global quality standards, and have a combined capacity to produce millions of units annually. Geographically, Pramodini Medicare has a strong presence across India and is expanding its footprint in emerging markets, leveraging a robust distribution network that includes partnerships with local distributors and healthcare providers. In the latest financial year, the company reported a total income of INR 500 crore, with a net profit of INR 50 crore, resulting in an EBITDA margin of 15%. The return on capital employed (ROCE) stands at 12%, while the return on equity (ROE) is recorded at 10%. The company's debt-equity ratio is a manageable 0.5, indicating a balanced approach to leveraging. The objectives of the upcoming IPO include funding expansion initiatives, enhancing manufacturing capacities, and repaying existing debt. Post-issue, the market capitalisation is expected to reach INR 1,500 crore, with an earnings per share (EPS) of INR 5 and a price-to-earnings (P/E) ratio of 30. Investor sentiment appears positive, driven by the company's growth potential and the increasing demand for healthcare products in the post-pandemic landscape.